Piperidine and morpholine derivatives and their use as therapeutic agents
    22.
    发明授权
    Piperidine and morpholine derivatives and their use as therapeutic agents 失效
    哌啶和吗啉衍生物及其作为治疗剂的用途

    公开(公告)号:US5985896A

    公开(公告)日:1999-11-16

    申请号:US981526

    申请日:1997-12-18

    CPC分类号: C07D405/14

    摘要: The present invention provides compounds of formula (I), wherein R.sup.1 is phenyl or a 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur, which aryl or heteroaryl group is optionally substituted; R.sup.2 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3, OCF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substituted by C.sub.1-4 alkoxy, where R.sup.a and R.sup.b each independently represent hydrogen or C.sub.1-4 alkyl; R.sup.4, R.sup.5, R.sup.6, R.sup.9a and R.sup.9b, A, X, and Y are as defined in the specification; the dotted line is an optional double bond; Q.sup.1 is oxygen, sulphur or --NH--; Q.sup.2 is --N.dbd., --NH--, --CH.dbd. or --CH.sub.2 --; and m is zero or 1; and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##

    摘要翻译: PCT No.PCT / GB96 / 01477 Sec。 371 1997年12月18日第 102(e)1997年12月18日PCT PCT 1996年6月20日PCT公布。 第WO97 / 01554号公报 日期1997年1月16日本发明提供式(I)化合物,其中R 1是苯基或含有1,2,3或4个选自氮,氧和硫的杂原子的5-或6-元芳族杂环基,其中 芳基或杂芳基任选被取代; R2是氢,卤素,C1-6烷基,C1-6烷氧基,CF3,OCF3,NO2,CN,SRa,SORa,SO2Ra,CO2Ra,CONRaRb,C2-6烯基,C2-6炔基或被C1-4烷氧基取代的C1-4烷基, R a和R b各自独立地表示氢或C 1-4烷基; R4,R5,R6,R9a和R9b,A,X和Y如说明书中所定义; 虚线是可选的双键; Q1是氧,硫或-NH-; Q2是-N =,-NH-,-CH =或-CH 2 - ; m为0或1; 及其药学上可接受的盐和前药。 该化合物特别用于治疗或预防疼痛,炎症,偏头痛,呕吐和带状疱疹后神经痛。

    Piperidine and morphonline derivatives and their use as therapeutic
agents
    23.
    发明授权
    Piperidine and morphonline derivatives and their use as therapeutic agents 失效
    哌啶和吗啉衍生物及其作为治疗剂的用途

    公开(公告)号:US5830892A

    公开(公告)日:1998-11-03

    申请号:US981294

    申请日:1997-12-18

    CPC分类号: C07D401/14

    摘要: The present invention provides compounds of formula (I), wherein R.sup.1 is a 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms selected from nitrogen, oxygen and sulphur, which group is optionally substituted; R.sup.2 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, CF.sub.3, OCF.sub.3, NO.sub.2, CN, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, CO.sub.2 R.sup.a, CONR.sup.a R.sup.b, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl or C.sub.1-4 alkyl substitued by C.sub.1-4 alkoxy, where R.sup.a and R.sup.a R.sup.b each independently represent hydrogen or C.sub.1-4 alkyl; R.sup.3 is hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 -alkoxy substituted by C.sub.1-4 alkoxy or CF.sub.3 ; R.sup.4, R.sup.5, R.sup.6, R.sup.9a, R.sup.9b, A, X and Y are as defined in the specification; and m is zero or , and pharmaceutically acceptable salts and prodrugs thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and pos therpetic neuralgia.

    摘要翻译: PCT No.PCT / GB96 / 01478 Sec。 371 1997年12月18日第 102(e)1997年12月18日PCT PCT 1996年6月20日PCT公布。 公开号WO97 / 01553 日期1997年1月16日本发明提供式(I)化合物,其中R 1是含有1,2,3或4个选自氮,氧和硫的杂原子的5或6元芳族杂环基,该基团任选地 取代 R2是氢,卤素,C1-6烷基,C1-6烷氧基,CF3,OCF3,NO2,CN,SRa,SORa,SO2Ra,CO2Ra,CONRaRb,C2-6烯基,C2-6炔基或C1-4烷氧基取代的C1-4烷基, Ra和RaRb各自独立地表示氢或C 1-4烷基; R3是氢,卤素,C1-6烷基,被C1-4烷氧基或CF3取代的C1-6烷氧基; R4,R5,R6,R9a,R9b,A,X和Y如说明书中所定义; 并且m为0或其药学上可接受的盐和前药。 该化合物特别用于治疗或预防疼痛,炎症,偏头痛,呕吐和炎症性神经痛。

    Spiro-piperidine derivatives and their use as tachykinin antagonists
    25.
    发明授权
    Spiro-piperidine derivatives and their use as tachykinin antagonists 失效
    螺哌啶衍生物及其作为速激肽拮抗剂的用途

    公开(公告)号:US6060469A

    公开(公告)日:2000-05-09

    申请号:US77063

    申请日:1998-05-18

    CPC分类号: C07D491/10

    摘要: The present invention relates to compounds of formula (I), ##STR1## wherein R.sup.1 represents halogen, hydroxy, C.sub.1-6 alkyl group optionally substituted by one or three fluorine atoms, C.sub.1-6 alkoxy group optionally substituted by one to three fluorine atoms, or C.sub.1-6 alkylthio optionally substituted by one to three fluorine atoms; R.sup.2 represents hydrogen, halogen, C.sub.1-6 alkyl or C.sub.1-6 alkoxy; or when R.sup.2 is adjacent to R.sup.1, they may be joined together such that there is formed a 5- or 6-membered saturated or unsaturated ring containing one or two oxygen atoms; R.sup.3 represents an optionally substituted 5- or 6-membered aromatic heterocyclic group containing 1, 2, 3 or 4 heteroatoms, selected from nitrogen, oxygen and sulphur; m is 0-3 and n is 0-3, with the proviso that the sum total of m+n is 2 or 3; p is zero or 1; q is 1 or 2; and when m is 1 and n is 1 or 2, the broken line represents an optional double bond; R.sup.4, R.sup.5, R.sup.6, R.sup.9 and R.sup.10 are a variety of substituents defined in the specification; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, emesis and postherpetic neuralgia.

    摘要翻译: PCT No.PCT / GB96 / 02853 Sec。 371日期1998年5月18日 102(e)日期1998年5月18日PCT提交1996年11月20日PCT公布。 公开号WO97 / 19084 日期:1997年5月29日本发明涉及式(I)化合物,其中R 1表示卤素,羟基,任选被一个或三个氟原子取代的C 1-6烷基,任选被一至三个氟原子取代的C 1-6烷氧基,或 任选被一至三个氟原子取代的C 1-6烷硫基; R 2表示氢,卤素,C 1-6烷基或C 1-6烷氧基; 或者当R 2与R 1相邻时,它们可以连接在一起,使得形成含有一个或两个氧原子的5-或6-元饱和或不饱和环; R3表示含有1,2,3或4个选自氮,氧和硫的杂原子的任选取代的5-或6-元芳族杂环基; m为0-3,n为0-3,条件是m + n的总和为2或3; p为零或1; q为1或2; 当m为1且n为1或2时,虚线表示任选的双键; R4,R5,R6,R9和R10是说明书中定义的各种取代基; 或其药学上可接受的盐。 该化合物特别用于治疗或预防疼痛,炎症,呕吐和带状疱疹后神经痛。

    Spiroketal derivatives, compositions containing them and their use as
therapeutic agents
    28.
    发明授权
    Spiroketal derivatives, compositions containing them and their use as therapeutic agents 失效
    螺缩酮衍生物,含有它们的组合物及其作为治疗剂的用途

    公开(公告)号:US5728695A

    公开(公告)日:1998-03-17

    申请号:US849969

    申请日:1997-06-20

    CPC分类号: C07D498/10

    摘要: The present invention relates to spiroketal derivatives of formula (I) and pharmaceutically acceptable salts thereof wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.9a, R.sup.9b, m and n are as defined in the specification, and to processes for their preparation, to intermediates used in their synthesis, to pharmaceutical compositions containing them, and to their use in therapy. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia. ##STR1##

    摘要翻译: PCT No.PCT / GB95 / 02927 Sec。 371日期:1997年6月20日 102(e)日期1996年6月20日PCT 1995年12月15日PCT PCT。 公开号WO96 / 20197 日本时间1996年7月4日本发明涉及式(I)的螺缩酮衍生物及其药学上可接受的盐,其中R1,R2,R3,R4,R5,R6,R9a,R9b,m和n如说明书中所定义, 其制备方法,其合成中使用的中间体,含有它们的药物组合物及其在治疗中的用途。 该化合物特别用于治疗或预防疼痛,炎症,偏头痛,呕吐和带状疱疹后神经痛。 (一)